ASH 2020 | IFM 209 update: 4-year extended follow-up of transplantation outcomes in myeloma

Aurore Perrot, MD, University of Toulouse, Toulouse, France, discusses the results of a 4-year extended follow up of the IFM 2009 study (NCT03679351) comparing lenalidomide, bortezomib and dexamethasone (RVd) therapy to RVd plus high-dose melphalan and autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma patients. With a median follow-up of over 90 months, the findings from 700 patients agreed with earlier results of significantly superior progression-free survival in the transplant arm, compared to RVd treatment alone. Measurable residual disease-negativity rates were also higher in the transplant group and were predictive of extended progression-free survival. Most patients who had disease progression in the RVd alone arm underwent delayed ASCT. There was no significant difference in overall survival between the two groups after 8 years, nor in the incidence of second primary malignancies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.